eli lilly retatrutide clinical trials VisualAbstract: reduces body weight by 17.5% in patients with obesity Lilly's triple agonist, retatrutide, delivered

This phenomenon, sometimes called tolerance or dose creep, is reported anecdotally with tirzepatide, though the clinical trial data does not show significant tolerance development at fixed doses over 72 weeks

Discover the GLP-1 hair care system designed to nourish and strengthen your hair for vibrant, healthy results every day

Customers who bought this item also bought

Understanding how to maintain benefits after stopping tirzepatide and how to wean off properly matters because some benefits may persist after discontinuation (improved metabolic health, resolved sleep apnea) while others may diminish (direct anti-inflammatory effects, lipid improvements)

Evidence is mixed

In support of this hypothesis, we did identify a weak association between the level of C-peptide and the level of ALT (Pearsons correlation coefficient = 0.30) and AST (Pearsons correlation coefficient = 0.29)